首页 > 最新文献

Allergy最新文献

英文 中文
Expansion of phenotypically modified type 2 memory B cells after allergen immunotherapy 过敏原免疫疗法后表型修饰的 2 型记忆 B 细胞的扩增
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2024-09-13 DOI: 10.1111/all.16320
Anouk von Borstel, Simone Reinwald, Pei M. Aui, Craig I. McKenzie, Nirupama Varese, P. Mark Hogarth, Mark Hew, Robyn E. O'Hehir, Menno C. van Zelm
{"title":"Expansion of phenotypically modified type 2 memory B cells after allergen immunotherapy","authors":"Anouk von Borstel, Simone Reinwald, Pei M. Aui, Craig I. McKenzie, Nirupama Varese, P. Mark Hogarth, Mark Hew, Robyn E. O'Hehir, Menno C. van Zelm","doi":"10.1111/all.16320","DOIUrl":"https://doi.org/10.1111/all.16320","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"12 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142231292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the editor: Efficacy of eHealth monitoring in pediatric asthma 致编辑的信:电子健康监测对小儿哮喘的疗效
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2024-09-13 DOI: 10.1111/all.16317
Casper E. W. Gijsen, Thijs R. P. Bogers, Jean W. M. Muris, Marieke W. P. van van Horck, Edward Dompeling
{"title":"Letter to the editor: Efficacy of eHealth monitoring in pediatric asthma","authors":"Casper E. W. Gijsen, Thijs R. P. Bogers, Jean W. M. Muris, Marieke W. P. van van Horck, Edward Dompeling","doi":"10.1111/all.16317","DOIUrl":"https://doi.org/10.1111/all.16317","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"74 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142231293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Establishment of an ELISA‐based in vitro test system to quantify the major honey bee venom allergen Api m 10 in crude bee venoms and therapy allergen products 建立基于酶联免疫吸附的体外测试系统,以定量检测粗蜂毒和治疗过敏原产品中的主要蜜蜂毒液过敏原 Api m 10
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2024-09-12 DOI: 10.1111/all.16313
Alisa Landgraf, Sascha Hein, Kathrin Elisabeth Paulus‐Tremel, Michelle Beatrice Wolff, Meike Arend, Ann‐Christine Junker, Daniel Strecker, Sascha Döring, Elke Völker, Thomas Holzhauser, Sandra Schmidt, Susanne Kaul, Stefan Schülke, Vera Mahler
{"title":"Establishment of an ELISA‐based in vitro test system to quantify the major honey bee venom allergen Api m 10 in crude bee venoms and therapy allergen products","authors":"Alisa Landgraf, Sascha Hein, Kathrin Elisabeth Paulus‐Tremel, Michelle Beatrice Wolff, Meike Arend, Ann‐Christine Junker, Daniel Strecker, Sascha Döring, Elke Völker, Thomas Holzhauser, Sandra Schmidt, Susanne Kaul, Stefan Schülke, Vera Mahler","doi":"10.1111/all.16313","DOIUrl":"https://doi.org/10.1111/all.16313","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"9 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of venom immunotherapy and sting challenge on HRQoL measured by venom‐allergy quality of life questionnaire (VQLQ) in Jack jumper ant allergic patients 毒液免疫疗法和毒刺挑战对通过毒液过敏生活质量问卷(VQLQ)测量杰克跳蚁过敏患者 HRQoL 的影响
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2024-09-12 DOI: 10.1111/all.16319
Kymble Spriggs, Elizabeth Leahy, Nicole Weibel, Sara Barnes
{"title":"Effect of venom immunotherapy and sting challenge on HRQoL measured by venom‐allergy quality of life questionnaire (VQLQ) in Jack jumper ant allergic patients","authors":"Kymble Spriggs, Elizabeth Leahy, Nicole Weibel, Sara Barnes","doi":"10.1111/all.16319","DOIUrl":"https://doi.org/10.1111/all.16319","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"6 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Algorithms in allergy: Diagnosis and management of atopic dermatitis in adulthood 过敏症治疗方案:成年期特应性皮炎的诊断和管理
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2024-09-11 DOI: 10.1111/all.16315
M. Grace Hren, Ester Del Duca, Helen He, Andrew L. Ji, Emma Guttman‐Yassky
{"title":"Algorithms in allergy: Diagnosis and management of atopic dermatitis in adulthood","authors":"M. Grace Hren, Ester Del Duca, Helen He, Andrew L. Ji, Emma Guttman‐Yassky","doi":"10.1111/all.16315","DOIUrl":"https://doi.org/10.1111/all.16315","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"149 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142170717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impaired calcium influx underlies skewed T helper cell differentiation in children with IgE-mediated food allergies. 钙离子流入障碍是 IgE 介导的食物过敏患儿 T 辅助细胞分化失衡的基础。
IF 12.6 1区 医学 Q1 ALLERGY Pub Date : 2024-09-09 DOI: 10.1111/all.16310
C L Lai, B Santner-Nanan, P J Maltese, C K S Ong, D J Palmer, D E Campbell, M Makrides, M Gold, R Nanan, S L Prescott, P S Hsu

Background: Reasons for Th2 skewing in IgE-mediated food allergies remains unclear. Clinical observations suggest impaired T cell activation may drive Th2 responses evidenced by increased atopic manifestations in liver transplant patients on tacrolimus (a calcineurin inhibitor). We aimed to assess differentiation potential, T cell activation and calcium influx of naïve CD4+ T cells in children with IgE-mediated food allergies.

Methods: Peripheral blood mononuclear cells from infants in the Starting Time for Egg Protein (STEP) Trial were analyzed by flow cytometry to assess Th1/Th2/Treg development. Naïve CD4+ T cells from children with and without food allergies were stimulated for 7 days to assess Th1/Th2/Treg transcriptional factors and cytokines. Store operated calcium entry (SOCE) was measured in children with and without food allergies. The effect of tacrolimus on CD4+ T cell differentiation was assessed by treating stimulated naïve CD4+ T cells from healthy volunteers with tacrolimus for 7 days.

Results: Egg allergic infants had impaired development of IFNγ+ Th1 cells and FoxP3+ transitional CD4+ T cells compared with non-allergic infants. This parallels reduced T-bet, IFNγ and FoxP3 expression in naïve CD4+ T cells from food allergic children after in vitro culture. SOCE of naïve CD4+ T cells was impaired in food allergic children. Naïve CD4+ T cells treated with tacrolimus had reduced IFNγ, T-bet, and FoxP3, but preserved IL-4 expression.

Conclusions: In children with IgE-mediated food allergies, dysregulation of T helper cell development is associated with impaired SOCE, which underlies an intrinsic impairment in Th1 and Treg differentiation. Along with tacrolimus-induced Th2 skewing, this highlights an important role of SOCE/calcineurin pathway in T helper cell differentiation.

背景:IgE 介导的食物过敏中 Th2 偏倚的原因仍不清楚。临床观察表明,T细胞活化受损可能会驱动Th2反应,服用他克莫司(一种钙神经蛋白抑制剂)的肝移植患者特应性表现增加就是证明。我们的目的是评估 IgE 介导的食物过敏患儿的分化潜能、T 细胞活化和幼稚 CD4+ T 细胞的钙离子流入:流式细胞术分析了鸡蛋蛋白起始时间(STEP)试验中婴儿的外周血单核细胞,以评估Th1/Th2/Treg的发育情况。对患有和未患有食物过敏症儿童的新生 CD4+ T 细胞进行为期 7 天的刺激,以评估 Th1/Th2/Treg 转录因子和细胞因子。对食物过敏儿童和非食物过敏儿童的储存操作钙离子通道(SOCE)进行了测量。用他克莫司刺激健康志愿者的幼稚 CD4+ T 细胞 7 天,评估他克莫司对 CD4+ T 细胞分化的影响:结果:与不过敏的婴儿相比,对鸡蛋过敏的婴儿的 IFNγ+ Th1 细胞和 FoxP3+ 过渡性 CD4+ T 细胞发育受损。这与体外培养后食物过敏儿童的幼稚 CD4+ T 细胞中 T-bet、IFNγ 和 FoxP3 表达减少的情况相似。食物过敏儿童的幼稚 CD4+ T 细胞的 SOCE 功能受损。用他克莫司处理的幼稚CD4+ T细胞的IFNγ、T-bet和FoxP3表达量减少,但IL-4表达量保持不变:结论:在IgE介导的食物过敏患儿中,T辅助细胞发育失调与SOCE受损有关,而SOCE受损是Th1和Treg分化内在障碍的基础。这与他克莫司诱导的Th2倾斜一起,凸显了SOCE/钙神经蛋白通路在T辅助细胞分化中的重要作用。
{"title":"Impaired calcium influx underlies skewed T helper cell differentiation in children with IgE-mediated food allergies.","authors":"C L Lai, B Santner-Nanan, P J Maltese, C K S Ong, D J Palmer, D E Campbell, M Makrides, M Gold, R Nanan, S L Prescott, P S Hsu","doi":"10.1111/all.16310","DOIUrl":"https://doi.org/10.1111/all.16310","url":null,"abstract":"<p><strong>Background: </strong>Reasons for Th2 skewing in IgE-mediated food allergies remains unclear. Clinical observations suggest impaired T cell activation may drive Th2 responses evidenced by increased atopic manifestations in liver transplant patients on tacrolimus (a calcineurin inhibitor). We aimed to assess differentiation potential, T cell activation and calcium influx of naïve CD4<sup>+</sup> T cells in children with IgE-mediated food allergies.</p><p><strong>Methods: </strong>Peripheral blood mononuclear cells from infants in the Starting Time for Egg Protein (STEP) Trial were analyzed by flow cytometry to assess Th1/Th2/Treg development. Naïve CD4<sup>+</sup> T cells from children with and without food allergies were stimulated for 7 days to assess Th1/Th2/Treg transcriptional factors and cytokines. Store operated calcium entry (SOCE) was measured in children with and without food allergies. The effect of tacrolimus on CD4<sup>+</sup> T cell differentiation was assessed by treating stimulated naïve CD4<sup>+</sup> T cells from healthy volunteers with tacrolimus for 7 days.</p><p><strong>Results: </strong>Egg allergic infants had impaired development of IFNγ<sup>+</sup> Th1 cells and FoxP3<sup>+</sup> transitional CD4<sup>+</sup> T cells compared with non-allergic infants. This parallels reduced T-bet, IFNγ and FoxP3 expression in naïve CD4<sup>+</sup> T cells from food allergic children after in vitro culture. SOCE of naïve CD4<sup>+</sup> T cells was impaired in food allergic children. Naïve CD4<sup>+</sup> T cells treated with tacrolimus had reduced IFNγ, T-bet, and FoxP3, but preserved IL-4 expression.</p><p><strong>Conclusions: </strong>In children with IgE-mediated food allergies, dysregulation of T helper cell development is associated with impaired SOCE, which underlies an intrinsic impairment in Th1 and Treg differentiation. Along with tacrolimus-induced Th2 skewing, this highlights an important role of SOCE/calcineurin pathway in T helper cell differentiation.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma 气道胰蛋白酶水平说明胰蛋白酶抑制剂 MTPS9579A 对哮喘缺乏临床疗效。
IF 12.6 1区 医学 Q1 ALLERGY Pub Date : 2024-09-09 DOI: 10.1111/all.16309
Horace Rhee, Lindsay M. Henderson, Rebecca N. Bauer, Kit Wong, Tracy L. Staton, David F. Choy, Prajna Banerjee, Victor Poon, Kenta Yoshida, Chen Chen, Keyi Long, Gizette Sperinde, Steven T. Laing, Nicholas S. Jones, Sara B. Glickstein, Parul Dayal, Alice Fong, Ajit Dash, Grazyna Pulka, Brian Leaker, Dave Singh, Peter Bradding

Background

Tryptase, a mast cell protease, has been identified as a potential therapeutic target in managing patients with refractory asthma. We assessed the efficacy, safety, pharmacokinetics, and pharmacodynamics of MTPS9579A, an anti-tryptase antibody, in a phase 2a randomized trial for patients with uncontrolled asthma and a phase 1c trial to understand activity within the lower respiratory tract.

Methods

Phase 2a patients (n = 134) received 1800 mg MTPS9579A or placebo intravenously every 4 weeks for 48 weeks. The primary endpoint was time to the first composite exacerbation event. Phase 1c patients (n = 27) received one intravenous dose of 300 or 1800 mg MTPS9579A or placebo. Both trials measured MTPS9579A concentrations and effects on tryptase in serum and nasal lining fluid; phase 1c also analyzed bronchial lining fluid.

Results

MTPS9579A did not meet the primary endpoint (hazard ratio = 0.90; 95% CI: 0.55–1.47; p = 0.6835); exacerbation rates in the placebo group were low. Serum and nasal MTPS9579A pharmacokinetics and tryptase levels were consistent with data from healthy volunteers. However, in phase 1c patients, compared to nasal levels, MTPS9579A bronchial concentrations were 6.8-fold lower, and bronchial active and total tryptase levels were higher (119-fold and 30-fold, respectively). Pharmacokinetic/pharmacodynamic modeling predicted intravenous doses of 3800 mg every 4 weeks would be necessary to achieve 95% active tryptase inhibition from baseline.

Conclusions

The MTPS9579A dose tested in the phase 2a study was insufficient to inhibit tryptase in bronchial lining fluid, likely contributing to the observed lack of efficacy.

背景:胰蛋白酶是一种肥大细胞蛋白酶,已被确定为治疗难治性哮喘患者的潜在靶点。我们评估了抗胰蛋白酶抗体 MTPS9579A 的疗效、安全性、药代动力学和药效动力学,2a 期随机试验针对未受控制的哮喘患者,1c 期试验旨在了解其在下呼吸道内的活性:2a期患者(n = 134)每4周静脉注射1800毫克MTPS9579A或安慰剂,共48周。主要终点是出现首次综合加重事件的时间。1c 期患者(27 人)静脉注射一次 300 或 1800 毫克 MTPS9579A 或安慰剂。两项试验均测定了血清和鼻腔黏膜液中的MTPS9579A浓度及其对胰蛋白酶的影响;1c期还分析了支气管黏膜液:MTPS9579A未达到主要终点(危险比=0.90;95% CI:0.55-1.47;P=0.6835);安慰剂组的病情恶化率较低。血清和鼻腔 MTPS9579A 药代动力学和胰蛋白酶水平与健康志愿者的数据一致。然而,在1c期患者中,与鼻腔水平相比,MTPS9579A支气管浓度低6.8倍,支气管活性和总胰蛋白酶水平更高(分别为119倍和30倍)。药代动力学/药效学模型预测,每4周静脉注射3800毫克的剂量才能使活性胰蛋白酶抑制率达到基线的95%:结论:2a期研究中测试的MTPS9579A剂量不足以抑制支气管内壁液中的胰蛋白酶,这可能是导致缺乏疗效的原因。
{"title":"Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma","authors":"Horace Rhee,&nbsp;Lindsay M. Henderson,&nbsp;Rebecca N. Bauer,&nbsp;Kit Wong,&nbsp;Tracy L. Staton,&nbsp;David F. Choy,&nbsp;Prajna Banerjee,&nbsp;Victor Poon,&nbsp;Kenta Yoshida,&nbsp;Chen Chen,&nbsp;Keyi Long,&nbsp;Gizette Sperinde,&nbsp;Steven T. Laing,&nbsp;Nicholas S. Jones,&nbsp;Sara B. Glickstein,&nbsp;Parul Dayal,&nbsp;Alice Fong,&nbsp;Ajit Dash,&nbsp;Grazyna Pulka,&nbsp;Brian Leaker,&nbsp;Dave Singh,&nbsp;Peter Bradding","doi":"10.1111/all.16309","DOIUrl":"10.1111/all.16309","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Tryptase, a mast cell protease, has been identified as a potential therapeutic target in managing patients with refractory asthma. We assessed the efficacy, safety, pharmacokinetics, and pharmacodynamics of MTPS9579A, an anti-tryptase antibody, in a phase 2a randomized trial for patients with uncontrolled asthma and a phase 1c trial to understand activity within the lower respiratory tract.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Phase 2a patients (<i>n</i> = 134) received 1800 mg MTPS9579A or placebo intravenously every 4 weeks for 48 weeks. The primary endpoint was time to the first composite exacerbation event. Phase 1c patients (<i>n</i> = 27) received one intravenous dose of 300 or 1800 mg MTPS9579A or placebo. Both trials measured MTPS9579A concentrations and effects on tryptase in serum and nasal lining fluid; phase 1c also analyzed bronchial lining fluid.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>MTPS9579A did not meet the primary endpoint (hazard ratio = 0.90; 95% CI: 0.55–1.47; <i>p</i> = 0.6835); exacerbation rates in the placebo group were low. Serum and nasal MTPS9579A pharmacokinetics and tryptase levels were consistent with data from healthy volunteers. However, in phase 1c patients, compared to nasal levels, MTPS9579A bronchial concentrations were 6.8-fold lower, and bronchial active and total tryptase levels were higher (119-fold and 30-fold, respectively). Pharmacokinetic/pharmacodynamic modeling predicted intravenous doses of 3800 mg every 4 weeks would be necessary to achieve 95% active tryptase inhibition from baseline.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The MTPS9579A dose tested in the phase 2a study was insufficient to inhibit tryptase in bronchial lining fluid, likely contributing to the observed lack of efficacy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":122,"journal":{"name":"Allergy","volume":"79 11","pages":"2993-3004"},"PeriodicalIF":12.6,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.16309","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of cytotoxic effector memory CD8+ T cells with sustained unresponsiveness after peanut oral immunotherapy. 细胞毒性效应记忆 CD8+ T 细胞与花生口服免疫疗法后持续无反应性的关系。
IF 12.6 1区 医学 Q1 ALLERGY Pub Date : 2024-09-07 DOI: 10.1111/all.16307
Hana Seastedt, Xiaorui Han, Andrea Fernandes, Stephen J Galli, Scott D Boyd, Kari C Nadeau, Monali Manohar, Sharon Chinthrajah
{"title":"Association of cytotoxic effector memory CD8<sup>+</sup> T cells with sustained unresponsiveness after peanut oral immunotherapy.","authors":"Hana Seastedt, Xiaorui Han, Andrea Fernandes, Stephen J Galli, Scott D Boyd, Kari C Nadeau, Monali Manohar, Sharon Chinthrajah","doi":"10.1111/all.16307","DOIUrl":"https://doi.org/10.1111/all.16307","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tissue levels of Alternaria allergen Alt a 1 reflect recurrence of refractory airway diseases. 组织中 Alternaria 过敏原 Alt a 1 的水平反映了难治性气道疾病的复发情况。
IF 12.6 1区 医学 Q1 ALLERGY Pub Date : 2024-09-07 DOI: 10.1111/all.16294
Yui Miyabe, Tomoe Abe, Toshiki Yamada, Tentaro Endo, Yohei Kawasaki, Shinsuke Suzuki, Misaki Arima, Shigeharu Ueki, Takechiyo Yamada
{"title":"Tissue levels of Alternaria allergen Alt a 1 reflect recurrence of refractory airway diseases.","authors":"Yui Miyabe, Tomoe Abe, Toshiki Yamada, Tentaro Endo, Yohei Kawasaki, Shinsuke Suzuki, Misaki Arima, Shigeharu Ueki, Takechiyo Yamada","doi":"10.1111/all.16294","DOIUrl":"https://doi.org/10.1111/all.16294","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to correspondence: “The effectiveness of pollen allergen immunotherapy on allergic rhinitis over 18 years: A national cohort study in Denmark” 对 "18 年来花粉过敏原免疫疗法对过敏性鼻炎的疗效:丹麦全国队列研究"。
IF 12.6 1区 医学 Q1 ALLERGY Pub Date : 2024-09-03 DOI: 10.1111/all.16312
Peter Bager, Jan Wohlfahrt, Mads Melbye
{"title":"Reply to correspondence: “The effectiveness of pollen allergen immunotherapy on allergic rhinitis over 18 years: A national cohort study in Denmark”","authors":"Peter Bager,&nbsp;Jan Wohlfahrt,&nbsp;Mads Melbye","doi":"10.1111/all.16312","DOIUrl":"10.1111/all.16312","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"79 10","pages":"2897-2898"},"PeriodicalIF":12.6,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142118483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Allergy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1